Drug manufacturer Merck is providing refunds for charges above 340B ceiling prices on 23 NDCs purchased during Q4 2019, Q3 2021, and Q2 2022.
The U.S. Health Resources and Services Administration posted Merck’s Nov. 21 notice about the repayments on its website late last week. Merck said the refunds are due to revised pricing data submitted to the Centers for Medicare & Medicaid Services.
Drug manufacturer Merck is providing refunds for charges above 340B ceiling prices on 23 NDCs purchased during Q4 2019, Q3 2021, and Q2 2022.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
